<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015339</url>
  </required_header>
  <id_info>
    <org_study_id>PAC-C</org_study_id>
    <secondary_id>ML22697</secondary_id>
    <nct_id>NCT01015339</nct_id>
  </id_info>
  <brief_title>Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction</brief_title>
  <official_title>A Randomized Multicenter Phase III Study Comparing Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment or Cisplatin Plus Capecitabine in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether Paclitaxel Plus Capecitabine With
      Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer is
      effective and safe.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse evens</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin plus capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel plus Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80mg/m2 infusion,d1,d8 every 3 weeks</description>
    <arm_group_label>Paclitaxel plus Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks</description>
    <arm_group_label>Paclitaxel plus Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks</description>
    <arm_group_label>Cisplatin plus capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>80mg/m2, day 1 of every 3 weeks</description>
    <arm_group_label>Cisplatin plus capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having signed informed consent

          -  Age≥ 18 years old

          -  Histologically confirmed gastric adenocarcinoma

          -  Unresectable recurrent or metastatic disease

          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more
             than 6 months

          -  Previous chemotherapy with capecitabine or cisplatin, if applicable, more than 12
             months.

          -  Measurable disease according to the RECIST criteria

          -  Karnofsky performance status ≥60

          -  Life expectancy of ≥2 month

          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than
             4 weeks

          -  ALT and AST&lt;2.5 times ULN (≤5 times ULN in patients with liver metastases)

          -  Serum albumin level ≥3.0g/dL

          -  Serum AKP &lt; 2.5 times ULN

          -  Serum creatinine &lt;ULN, and CCr &lt; 60ml/min

          -  Bilirubin level &lt; 1.5 ULN

          -  WBC&gt;3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl

        Exclusion Criteria:

          -  Brain metastasis (known or suspected)

          -  Previous systemic therapy for metastatic gastric cancer

          -  Inability to take oral medication

          -  Previous therapy targeting at angiogenesis or vasculogenesis pathway or other targeted
             therapy

          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry

          -  Contraindications of nuclear magnetic resonance image such as fitment of cardiac
             pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball
             and so on.

          -  Allergic constitution or allergic history to protium biologic product or any
             investigating agents.

          -  Severe heart disease or such history as recorded congestive heart failure,
             uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve
             disease, severe abnormal ECG findings, cardiac infarction , or retractable
             hypertension.

          -  Pregnancy or lactation period

          -  Any investigational agent within the past 28 days

          -  Other previous malignancy within 5 year, except non-melanoma skin cancer

          -  Previous adjuvant therapy with capecitabine+platinum,

          -  Pre-existing neuropathy&gt;grade 1

          -  Legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University, School of oncology, Department of GI oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhihao Lu, MD</last_name>
    <phone>86-10-88196561</phone>
    <email>pppeirain@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fu Chen, Bachelor</last_name>
    <phone>86-10-88196561</phone>
    <email>kimandking@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of GI Oncology, Peking University, School of Oncology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihao Lu, MD</last_name>
      <phone>86-10-88196561</phone>
      <email>pppeirain@126.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

